Treatment and management of FXTAS

Deborah A. Hall, Maureen A. Leehey, Elizabeth Berry-Kravis, Randi J Hagerman

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Fragile X-associated tremor/ataxia syndrome (FXTAS) affects older adult carriers of the FMR1 premutation and can be associated with a broad array of clinical symptoms and presentations including tremor, ataxia, parkinsonism, executive function disturbance and dementia, psychiatric symptoms of anxiety, depression and disinhibition, peripheral neuropathy, autonomic dysfunction, hormonal dysfunction, and pain syndromes. Although controlled trials have not demonstrated efficacy for FXTAS symptoms, there is information available regarding symptomatic treatments. Treatment is generally supportive, directed at component symptoms that are most problematic, and makes use of evidence regarding effectiveness of medications and other interventions for treatment of disorders that have phenotypic overlap with FXTAS. This chapter summarizes available treatments and supports that can be helpful for persons with FXTAS.

Original languageEnglish (US)
Title of host publicationFXTAS, FXPOI, and Other Premutation Disorders
PublisherSpringer International Publishing
Pages181-197
Number of pages17
ISBN (Electronic)9783319338989
ISBN (Print)9783319338965
DOIs
StatePublished - Jan 1 2016

Fingerprint

Executive Function
Parkinsonian Disorders
Peripheral Nervous System Diseases
Tremor
Ataxia
Therapeutics
Psychiatry
Dementia
Anxiety
Depression
Pain
Fragile X Tremor Ataxia Syndrome

Keywords

  • Ataxia
  • Deep brain stimulation
  • Memantine
  • Parkinsonism
  • Therapy
  • Treatment
  • Tremor

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)

Cite this

Hall, D. A., Leehey, M. A., Berry-Kravis, E., & Hagerman, R. J. (2016). Treatment and management of FXTAS. In FXTAS, FXPOI, and Other Premutation Disorders (pp. 181-197). Springer International Publishing. https://doi.org/10.1007/978-3-319-33898-9_9

Treatment and management of FXTAS. / Hall, Deborah A.; Leehey, Maureen A.; Berry-Kravis, Elizabeth; Hagerman, Randi J.

FXTAS, FXPOI, and Other Premutation Disorders. Springer International Publishing, 2016. p. 181-197.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hall, DA, Leehey, MA, Berry-Kravis, E & Hagerman, RJ 2016, Treatment and management of FXTAS. in FXTAS, FXPOI, and Other Premutation Disorders. Springer International Publishing, pp. 181-197. https://doi.org/10.1007/978-3-319-33898-9_9
Hall DA, Leehey MA, Berry-Kravis E, Hagerman RJ. Treatment and management of FXTAS. In FXTAS, FXPOI, and Other Premutation Disorders. Springer International Publishing. 2016. p. 181-197 https://doi.org/10.1007/978-3-319-33898-9_9
Hall, Deborah A. ; Leehey, Maureen A. ; Berry-Kravis, Elizabeth ; Hagerman, Randi J. / Treatment and management of FXTAS. FXTAS, FXPOI, and Other Premutation Disorders. Springer International Publishing, 2016. pp. 181-197
@inbook{4a870181ff0749f9a83e21a11f06f9c5,
title = "Treatment and management of FXTAS",
abstract = "Fragile X-associated tremor/ataxia syndrome (FXTAS) affects older adult carriers of the FMR1 premutation and can be associated with a broad array of clinical symptoms and presentations including tremor, ataxia, parkinsonism, executive function disturbance and dementia, psychiatric symptoms of anxiety, depression and disinhibition, peripheral neuropathy, autonomic dysfunction, hormonal dysfunction, and pain syndromes. Although controlled trials have not demonstrated efficacy for FXTAS symptoms, there is information available regarding symptomatic treatments. Treatment is generally supportive, directed at component symptoms that are most problematic, and makes use of evidence regarding effectiveness of medications and other interventions for treatment of disorders that have phenotypic overlap with FXTAS. This chapter summarizes available treatments and supports that can be helpful for persons with FXTAS.",
keywords = "Ataxia, Deep brain stimulation, Memantine, Parkinsonism, Therapy, Treatment, Tremor",
author = "Hall, {Deborah A.} and Leehey, {Maureen A.} and Elizabeth Berry-Kravis and Hagerman, {Randi J}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-33898-9_9",
language = "English (US)",
isbn = "9783319338965",
pages = "181--197",
booktitle = "FXTAS, FXPOI, and Other Premutation Disorders",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Treatment and management of FXTAS

AU - Hall, Deborah A.

AU - Leehey, Maureen A.

AU - Berry-Kravis, Elizabeth

AU - Hagerman, Randi J

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Fragile X-associated tremor/ataxia syndrome (FXTAS) affects older adult carriers of the FMR1 premutation and can be associated with a broad array of clinical symptoms and presentations including tremor, ataxia, parkinsonism, executive function disturbance and dementia, psychiatric symptoms of anxiety, depression and disinhibition, peripheral neuropathy, autonomic dysfunction, hormonal dysfunction, and pain syndromes. Although controlled trials have not demonstrated efficacy for FXTAS symptoms, there is information available regarding symptomatic treatments. Treatment is generally supportive, directed at component symptoms that are most problematic, and makes use of evidence regarding effectiveness of medications and other interventions for treatment of disorders that have phenotypic overlap with FXTAS. This chapter summarizes available treatments and supports that can be helpful for persons with FXTAS.

AB - Fragile X-associated tremor/ataxia syndrome (FXTAS) affects older adult carriers of the FMR1 premutation and can be associated with a broad array of clinical symptoms and presentations including tremor, ataxia, parkinsonism, executive function disturbance and dementia, psychiatric symptoms of anxiety, depression and disinhibition, peripheral neuropathy, autonomic dysfunction, hormonal dysfunction, and pain syndromes. Although controlled trials have not demonstrated efficacy for FXTAS symptoms, there is information available regarding symptomatic treatments. Treatment is generally supportive, directed at component symptoms that are most problematic, and makes use of evidence regarding effectiveness of medications and other interventions for treatment of disorders that have phenotypic overlap with FXTAS. This chapter summarizes available treatments and supports that can be helpful for persons with FXTAS.

KW - Ataxia

KW - Deep brain stimulation

KW - Memantine

KW - Parkinsonism

KW - Therapy

KW - Treatment

KW - Tremor

UR - http://www.scopus.com/inward/record.url?scp=85018891119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018891119&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-33898-9_9

DO - 10.1007/978-3-319-33898-9_9

M3 - Chapter

SN - 9783319338965

SP - 181

EP - 197

BT - FXTAS, FXPOI, and Other Premutation Disorders

PB - Springer International Publishing

ER -